Medically reviewed by Casey Gallagher, MD Atopic dermatitis (AD) is a chronic (long-term) skin condition that causes itchy, ...

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

Tofacitinib, a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address ...

Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

A new study in Scientific Reports reveals that skin shame is a key psychological burden for people with atopic dermatitis and ...

In adults with atopic dermatitis, moisturizers with anti-inflammatory ingredients significantly improved skin hydration and ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 ...

A panelist discusses how real-world data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) ...

Patients with early-onset atopic dermatitis, especially those with severe atopic dermatitis, are more likely to develop pediatric uveitis.

"In the phase 3 randomized clinical trial, once-daily oral ivarmacitinib (4 or 8 mg) led to significant improvements in the ...

Galderma has kicked off an ad campaign to show how its Nemluvio can empower people to rule over itchy eczema. Aiming to grow ...

More information on the KT-621 BroADen trial in AD will be available on www.clinicaltrials.gov. Atopic dermatitis (AD) is the most common form of eczema, a chronic inflammatory disease that causes the ...